Edesa Biotech Inc (EDSA)
1.96
-0.05
(-2.49%)
USD |
NASDAQ |
May 23, 16:00
1.98
+0.02
(+1.02%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 13.76M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -56.10% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 22.53 |
| Price to Book Value | 2.166 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.41% |
Profile
Edit
| Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development. |
| URL | https://www.edesabiotech.com |
| Investor Relations URL | http://ir.stellarbiotechnologies.com/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 08, 2025 (est.) |
| Last Earnings Release | May. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development. |
| URL | https://www.edesabiotech.com |
| Investor Relations URL | http://ir.stellarbiotechnologies.com/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 08, 2025 (est.) |
| Last Earnings Release | May. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |